<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691158</url>
  </required_header>
  <id_info>
    <org_study_id>eIRB #2168</org_study_id>
    <secondary_id>OCTRI #933</secondary_id>
    <nct_id>NCT00691158</nct_id>
  </id_info>
  <brief_title>A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide</brief_title>
  <official_title>A Pilot Study of the fMRI Response to Leptin and Pramlintide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify how certain parts of the brain that help control
      body weight respond to an infusion of hormones called leptin and amylin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following an overnight fast, subjects will undergo fMRI measurements of the hypothalamus,
      brainstem and whole brain during an infusion of either normal saline, pramlintide, leptin, or
      the combination leptin and pramlintide.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the fMRI response in the hypothalamus and brainstem, and whole brain, to intravenous leptin, pramlintide, combination leptin and pramlintide, and saline control.</measure>
    <time_frame>over 90 minutes</time_frame>
    <description>measurements at each study time are include fMRI, blood draws and Visual Analog Score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed blood samples during infusion will establish the time course for peak levels of infused hormones as well as detectable changes in insulin and glucose levels.</measure>
    <time_frame>over 90 minutes</time_frame>
    <description>Blood samples are taken every 5 minutes from Timepoint +0 to Timepoint +60 and again one time at Timepoint +90</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1- Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4.7 mls normal saline IV bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Metreleptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Leptin bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Pramlintide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Pramlintide bolus at Timpoint +0 and +30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Leptin plus Pramlintide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide (Amylin)</intervention_name>
    <description>4.7 mls of Amylin 15mcg/ml IV bolus.</description>
    <arm_group_label>3 Pramlintide</arm_group_label>
    <other_name>Amylin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Normal Saline)</intervention_name>
    <description>4.7 mls normal saline IV bolus x1</description>
    <arm_group_label>1- Normal Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 Metreleptin</intervention_name>
    <description>Receive .06mg/kg of metreleptin IV bolus x1</description>
    <arm_group_label>2 Metreleptin</arm_group_label>
    <other_name>Leptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leptin plus Pramlintide</intervention_name>
    <description>receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.</description>
    <arm_group_label>4 Leptin plus Pramlintide</arm_group_label>
    <other_name>Leptin and Amylin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 year to 45 years of age

          -  MI 18 to 25 kg/m2 or â‰¥ 30 kg/m2

          -  At maximal lifetime weight

          -  Weight stable for at least 3 months

        Exclusion Criteria:

          -  Those with a major medical illness or who require prescription medication, including:
             cancer, coronary artery disease, hypertension, and diabetes.

          -  Subjects taking psychiatric or centrally-acting (CNS) medications or who are diagnosed
             with a psychiatric or neurological illness, including:

               -  depression

               -  anorexia

               -  bulimia

               -  seizure disorder.

          -  Exercise &gt; 30 minutes, 3 times a week

          -  Alcohol consumption &gt; 2 drinks / day

          -  Weight &gt; 350 lbs (159 kg) (weight limit for MR machine)

          -  Illicit drug use

          -  Pregnancy

          -  Extreme dietary habits as determined by a GCRC nutritionist: very high or low dietary
             carbohydrate or fat intakes

          -  Those with a contraindication to exposure to strong magnetic fields: presence of metal
             in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips

          -  Those with claustrophobia

          -  Anaphylaxis and known hypersensitivity to E. coli-derived proteins

          -  Allergies or contraindications to metreleptin or pramlintide

          -  Renal or hepatic impairment

          -  Women who are lactating

          -  Tobacco use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Q. Purnell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU - Center for the Study of Weight Regulation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jonathan Purnell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

